Joint Statement by the Korean Endocrine Society, Korean Diabetes Association, and Korean Society for the Study of Obesity
"Inspect Repeated or Bulk Imports Suspected of Resale"
Urge Coverage Discussions for Patients with Diabetes and Severe Obesity

With individuals now allowed to personally carry into the country GLP-1 (glucagon-like peptide-1) obesity and diabetes medications prescribed overseas, medical societies have called on the government to establish procedures for verifying prescriptions and purchases and to crack down on illegal distribution.


"Mounjaro Brought in from Overseas: Prescription and Purchase Verification Process Needed" View original image

The Korean Endocrine Society, the Korean Diabetes Association and the Korean Society for the Study of Obesity issued a joint statement on November 17, urging the government to establish effective verification procedures and specific safety measures to prevent prescription drugs brought in from overseas from being misused or abused in Korea.


The Ministry of Food and Drug Safety and the Korea Customs Service announced that, starting November 12, individuals could personally carry in up to six units of medication for self-treatment, provided the drugs were formally approved under the regular medical system of the country concerned and had been prescribed and purchased there.


The societies said they understood that the government’s measure was intended to reduce inconvenience for the public and foreign nationals residing in Korea, but stressed that “setting standards for personal import does not change domestic approval requirements or the principles of appropriate prescribing.” They said that “telemedicine can also involve appropriate assessment and prescribing by a physician,” but pointed out that “safety is difficult to guarantee if the purpose of the prescription, dosage and approval status cannot be verified, or if patients are not connected with medical professionals in Korea who can monitor their treatment.”


They therefore proposed establishing a procedure for submitting documents that verify whether patients personally obtained prescriptions and purchased the drugs from overseas medical institutions. The documents should include the patient’s identifying information, the drug name, dosage and quantity, and the prescribing institution and date. They added that rather than requiring diagnoses or full medical histories across the board, authorities should verify only necessary information and minimize the handling of personal data.


The societies also called for greater cooperation and inspections among relevant agencies in cases where repeated or large-volume imports raise suspicions of resale, and for ongoing monitoring of person-to-person drug sales through online secondhand marketplaces and social networking services (SNS). They also said a system was needed to provide guidance, before and after entry into Korea, on approved uses, how to respond to adverse reactions, and precautions for refrigerated storage and transportation.


They also called for the health insurance coverage process for Mounjaro as a treatment for type 2 diabetes to be completed promptly, and for discussions to begin on coverage for patients who need drug treatment for severe obesity or obesity-related comorbidities. They urged pharmaceutical companies to take an active role in lowering drug prices and securing insurance coverage. “The widening gap between drug prices at home and abroad and the burden of out-of-pocket costs are among the reasons more people are traveling overseas to purchase these drugs,” the societies said. “We must address both the cost burden and access to treatment so that patients who need treatment can use appropriate medications.”



The societies urged patients who have obtained prescriptions for medications overseas and brought them into Korea to consult with local medical professionals before use, informing them of the drug name, dosage, prescription and use history, and storage conditions. They stressed that “prescription drugs must not be shared with or sold to others, and injectable drugs bought through online or person-to-person transactions should not be purchased because it is difficult to verify their authenticity and storage conditions.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing